GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (4)
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 16_Supplement ( 2020-08-15), p. 257-257
    Abstract: Colorectal cancer (CRC) ranks as the second most common non-sex-specific cancer worldwide and the second cause of cancer deaths. Screening programs for CRC based on the fecal immunochemical test (FIT) are effective in average-risk population for the tumor detection but has low sensitivity for the recognition of advanced adenomas. We identified microRNA (miRNA) signatures by next-generation sequencing in fecal samples that could detect patients with adenomas or CRC. The same signatures were also evaluated in plasma extracellular vesicles (EVs) from the same patients. A genome-wide miRNA expression profiling was initially performed in 221 subjects (80 healthy subjects; 43 adenoma patients; 41 individuals with inflammatory bowel disease [IBD]; and 57 CRC) recruited in a cross-sectional study in Italy where stool and plasma samples have been consecutively collected at colonoscopy. Several differentially expressed miRNAs, mostly in stool samples, have been identified both in common or peculiar of specific comparison among the 3 categories of patients vs healthy subjects. Subsequently, a similar profiling has been performed for a set of 24 paired colorectal tumor and adjacent non-tumor samples from the group of CRC patients already samples for stool and plasma. Several miRNAs (n=137) resulted altered in cancer tissues compared to non-tumor; on the other hand, 91 miRNAs resulted altered in stool and only 6 in plasma EVs. Analyzing stool samples from the whole Italian cohort we observed a good overlap of the altered miRNAs observed in tissues (miR-148a-3p, miR-182-5p, miR-143-3p, miR-12136-3p; miR-378a-3p, miR-1290-5p, miR-21-5p, miR-7704-3p). The identified differentially expressed miRNAs in stool and plasma EVs were validated in an independent cohort from the Czech Republic (22 healthy, 19 Inflammation, 21 Adenoma, 34 CRC) with a similar approach. Preliminary results in this independent cohort showed that 19, 12 and 7 miRNAs were differentially expressed when comparing CRC with healthy, CRC and adenoma and inflammation individuals, respectively. In the comparison of CRC versus healthy subjects we observed a good overlap of miRNAs differentially expressed between the Czech and Italian cohorts: 10 miRNAs (miR-148a-3p, miR-1181-3p, miR-1290-5p, miR-4488-3p, miR-1246-3p, let-7i-5p, let-7b-5p, miR-4497-3p, miR-21-5p, miR-149-3p) were significantly altered in the same directions in the 2 cohorts. Moreover, hsa-miR-1290-5p and hsa-miR-4488-3p resulted significantly upregulated when going from healthy, inflammation, adenoma and CRC both in the Italian and in the Czech cohorts. Finally, with the application of a multi-class machine learning approach, we identified a signature of 13 miRNAs whose expression was able to accurately classify (AUC = 0.90) the four classes of subjects in combination with the information of patient age and sex. These results showed that there could be a potential application of the analyses of nucleic acids in stool as adjuvant in non-invasive screening. Citation Format: Sonia Tarallo, Antonio Francavilla, Giulio Ferrero, Francesca Cordero, Gaetano Gallo, Andrew Maltez Thomas, Paolo Manghi, Veronika Vymetalkova, Ludmila Vodickova, Nicola Segata, Pavel Vodicka, Barbara Pardini, Alessio Naccarati. Whole miRNome profiling in fecal and plasma exosome samples for the diagnosis of colorectal cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 257.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 10, No. 8 ( 2004-04-15), p. 2824-2831
    Abstract: Purpose: The purpose is to evaluate the expression of CD40, a membrane protein predominantly expressed on B cells, dendritic cells, and macrophages, in a series of adult soft tissue sarcomas and to test its possible prognostic value. Experimental Design: CD40 expression was studied by immunohistochemistry. Correlations with other baseline characteristics of patients and tumors were analyzed with χ2 test. The prognostic value was studied with univariable and multivariable analysis adjusted by age, sex, tumor size, grade, location, and distant metastases. Results: Eighty-two patients, between January 1994 and May 2001, were analyzed. Membrane or cytoplasmic staining for CD40 protein was absent in 30% of the tumors but present in & lt;10% of cells in 22 (27%), in 10% to 50% in 23 (28%), and in & gt;50% of cells in 12 (15%) tumors. There was no correlation between CD40 expression and age, sex, size, grade, and location of the primary tumor and distant metastases. With 61 patients (74.4%) progressed and 31 (37.8%) dead, CD40 expression was a significant prognostic factor for disease-free and overall survival at univariable and multivariable analysis. Patients with tumors expressing CD40 in & gt;50% of cells had a dramatically unfavorable prognosis with median disease-free and overall survival of 7 and 17 months, respectively, and hazard ratios of relapse and death as compared with patients with CD40-negative tumors of 2.89 (95% confidence interval: 1.26–6.60) and 6.92 (95% confidence interval: 2.18–22.0), respectively. Conclusions: These data suggest that expression of CD40 protein in & gt;50% of cells might indicate an unfavorable prognosis in adult soft tissue sarcomas.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2004
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 77, No. 13_Supplement ( 2017-07-01), p. LB-330-LB-330
    Abstract: MicroRNAs (miRNAs) are key gene regulators in most biological and pathological processes, including colorectal cancer (CRC). The possibility of using circulating or fecal miRNA expression levels as non-invasive biomarkers open interesting possibilities for their potential clinical utility. Next-generation sequencing (NGS) technologies have changed the approach to complex genomic studies, including those on noncoding RNAs, providing a reliable and accurate method for grouping individuals on the basis of their molecular profiles. We report our study on the search of CRC biomarkers in surrogate specimens by a concomitant evaluation of miRNA expression profiles in plasma and stool samples from healthy subjects and patients with CRC or precancerous lesions. In particular, miRNA expression profiles were characterized by NGS (small RNA sequencing) in exosome isolated from plasma and in stool samples of a discovery set (n=130) of CRC/adenoma/inflammatory disease patients and healthy subjects recruited at colonoscopy. An optimized workflow for miRNAs quantification from NGS and an analysis pipeline has been developed for pre-processing the raw sequences, aligning the data to a known reference sequence and finally, analyzing the compiled sequence. Information on lifestyle and dietary habits were collected at the time of enrolment, together with biological samples. Preliminary results of a set of 96 plasma/stool samples showed that several miRNAs resulted dysregulated in all categories of subjects with disease in comparison with healthy subjects. In particular, in stool of CRC patients more than 140 miRNAs showed altered expression levels in comparison with healthy controls after adjusting for multiple testing. Among them, we have recorded miRNAs already observed in primary tissue, such as over-expressed miR-92a and miR-21, but also miRNAs previously not described. A group of eleven miRNAs showed similar trends between plasma and stool samples. The most relevant identified dysregulated miRNAs will be validated by qPCR in an additional group with similar distributions of cases/controls. The present study shows the importance to use high-throughput techniques and complex computational analyses to globally define miRNA signatures involved in colorectal carcinogenesis in surrogate specimens. Stool miRNAs analyzed by NGS for the first time in the present study seem to provide reliable and comparable results to other specimens (number of mapped sequences/identified miRNAs). Their future use in clinical practice may help to avoid unnecessary and expensive colonoscopies in low-risk patients. Citation Format: Alessio Naccarati, Sonia Tarallo, Gaetano Gallo, Giulio Ferrero, Antonio Francavilla, Giuseppe Clerico, Alberto Realis, Mario Trompetto, Francesca Cordero, Barbara Pardini, Paolo Vineis. Stool and plasma miRNA profiles by next-generation sequencing: a study on subjects with colorectal cancer and precancerous lesions [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-330. doi:10.1158/1538-7445.AM2017-LB-330
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 16_Supplement ( 2020-08-15), p. 269-269
    Abstract: Colorectal cancer (CRC) is one of the most frequent cancers worldwide. The available screening tests have reduced the incidence and mortality for this cancer; however, the research of new potential molecular biomarkers to use concomitantly could improve advanced adenomas/CRC early detection. Small non-coding RNAs (sncRNAs) are stable, easy detectable molecules that have been found dysregulated in several diseases including CRC. Besides the most studied microRNAs (miRNAs), sncRNAs include also P-element-induced wimpy testis (PIWI)-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs), transfer RNAs (tRNAs) and other miscellaneous RNAs, all with key roles in post-transcriptional regulation. The aim of the present study was to identify by next-generation sequencing (NGS) signatures of sncRNAs other than miRNAs, in fecal and plasma extracellular vesicles (EVs) samples potentially able to detect patients with adenomas or CRC. We initially performed a small RNA-sequencing in samples from 221 subjects collected at colonoscopy. The group included: i) 80 healthy subjects with negative colonoscopy results; (ii) 43 adenoma patients; (iii) 41 individuals with inflammatory bowel disease and (iv) 57 newly diagnosed CRC patients. A computational pipeline for the identification of sncRNAs after miRNA mapping reads was previously implemented by our group. In stool samples, comparing the categories of interest mentioned above, we identified 395 differentially expressed sncRNAs (DEsncRNAs), mainly piRNAs (46.3%) and tRNAs (43.6%) (likelihood ratio test adjusting for sex and age, FDR adjusted p ≤ 0.05). Similarly, a group of 32 DEsncRNAs was detected in plasma EVs with piRNAs (41%) and tRNAs (44%) resulting among the most altered. Small RNA-sequencing has also been performed in a subset of 24 paired colorectal tumor and adjacent non-malignant tissues from the CRC patients for whom stool and plasma samples were analysed. Fifty-seven DEsncRNAs were found in tumor vs. non-malignant adjacent tissue with a similar distribution of dysregulated sncRNA biotypes. Some DEsncRNAs were shared between stool and tissues (n=35), plasma EVs and tissues (n=11) and, interestingly, among the profiles of the three different biospecimens (n=10). To validate our findings, we also sequenced stool samples from an independent cohort from the Czech Republic (at present 22 healthy subjects, 19 with inflammations, 21 with adenomas and 34 CRC patients). A total of 100 DEsncRNAs were detected in this validation cohort, among which 43 overlapped with those detected in the Italian cohort. In conclusions, we show that besides the most widely performed miRNA profiling, also the detection of sncRNAs in surrogate tissues by NGS may help to identify reliable and comparable results with those of primary tissues. To further investigate these molecules may provide new accurate markers for CRC diagnostic purposes. Citation Format: Antonio Francavilla, Sonia Tarallo, Giulio Ferrero, Francesca Cordero, Gaetano Gallo, Veronika Vymetalkova, Ludmila Vodickova, Pavel Vodicka, Barbara Pardini, Alessio Naccarati. Small non-coding RNA profiling in stool and plasma samples to explore potential biomarkers for colorectal cancer diagnosis [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 269.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...